Literature DB >> 36102635

Ceftazidime-Avibactam plus Aztreonam for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria.

Abiu Sempere1,2, Belén Viñado3,4, Ibai Los-Arcos1,2,4, David Campany5, Nieves Larrosa2,3,4,6, Nuria Fernández-Hidalgo1,2,4,6, Dolors Rodríguez-Pardo1,2,4,6, Juan José González-López2,3,4,6, Xavier Nuvials2,7,8, Benito Almirante1,2,4,6, Laura Escolà-Vergé1,2,4,6.   

Abstract

This is a retrospective single-center study of 24 patients who received ceftazidime-avibactam plus aztreonam (CZA/ATM) for the treatment of VIM-type-producing Gram-negative bacillus (GNB) infections. The bacteria isolated were Enterobacterales in 22 patients and Pseudomonas aeruginosa in 2. Sixteen out of 19 isolates showed synergistic activity. Two patients presented clinical failure at day 14, and the 30-day mortality was 17% (4/24). CZA/ATM could be considered an alternative therapy for VIM-type-producing GNB infections.

Entities:  

Keywords:  MBL; VIM; aztreonam; ceftazidime-avibactam; metallo-β-lactamase

Mesh：

Substances：

Year:  2022        PMID： 36102635      PMCID： PMC9578418          DOI： 10.1128/aac.00751-22

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.938


  13 in total

1.  Comparison of 3 Etest(®) methods and time-kill assay for determination of antimicrobial synergy against carbapenemase-producing Klebsiella species.

Authors:  George A Pankey; Deborah S Ashcraft; Adriana Dornelles
Journal:  Diagn Microbiol Infect Dis       Date:  2013-08-28       Impact factor: 2.803

2.  Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection.

Authors:  Evelyn Shaw; Alexander Rombauts; Fe Tubau; Ariadna Padullés; Jordi Càmara; Toni Lozano; Sara Cobo-Sacristán; Núria Sabe; Imma Grau; Raül Rigo-Bonnin; M Angeles Dominguez; Jordi Carratalà
Journal:  J Antimicrob Chemother       Date:  2018-04-01       Impact factor: 5.790

3.  Aztreonam Combination Therapy: An Answer to Metallo-β-Lactamase-Producing Gram-Negative Bacteria?

Authors:  Ryan K Shields; Yohei Doi
Journal:  Clin Infect Dis       Date:  2020-08-14       Impact factor: 9.079

Review 4.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.

Authors:  Jesús Rodríguez-Baño; Belén Gutiérrez-Gutiérrez; Isabel Machuca; Alvaro Pascual
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

Review 5.  Defining the Role of Novel β-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms.

Authors:  Pranita D Tamma; Alice J Hsu
Journal:  J Pediatric Infect Dis Soc       Date:  2019-07-01       Impact factor: 3.164

6.  Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?

Authors:  Steven Marshall; Andrea M Hujer; Laura J Rojas; Krisztina M Papp-Wallace; Romney M Humphries; Brad Spellberg; Kristine M Hujer; Emma K Marshall; Susan D Rudin; Federico Perez; Brigid M Wilson; Ronald B Wasserman; Linda Chikowski; David L Paterson; Alejandro J Vila; David van Duin; Barry N Kreiswirth; Henry F Chambers; Vance G Fowler; Michael R Jacobs; Mark E Pulse; William J Weiss; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

7.  European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine).

Authors:  Mical Paul; Elena Carrara; Pilar Retamar; Thomas Tängdén; Roni Bitterman; Robert A Bonomo; Jan de Waele; George L Daikos; Murat Akova; Stephan Harbarth; Celine Pulcini; José Garnacho-Montero; Katja Seme; Mario Tumbarello; Paul Christoffer Lindemann; Sumanth Gandra; Yunsong Yu; Matteo Bassetti; Johan W Mouton; Evelina Tacconelli; Jesús Rodríguez-Baño
Journal:  Clin Microbiol Infect       Date:  2021-12-16       Impact factor: 8.067

8.  Combination of aztreonam, ceftazidime-avibactam and amikacin in the treatment of VIM-1 Pseudomonas aeruginosa ST235 osteomyelitis.

Authors:  Alessandra Mularoni; Maria Lina Mezzatesta; Michele Pilato; Alice Annalisa Medaglia; Adriana Cervo; Dafne Bongiorno; Ausilia Aprile; Angelo Luca; Stefania Stefani; Paolo Grossi
Journal:  Int J Infect Dis       Date:  2021-06-04       Impact factor: 3.623

9.  Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).

Authors:  Pranita D Tamma; Samuel L Aitken; Robert A Bonomo; Amy J Mathers; David van Duin; Cornelius J Clancy
Journal:  Clin Infect Dis       Date:  2021-04-08       Impact factor: 9.079
View more
  1 in total

1.  Ceftazidime-Avibactam plus Aztreonam for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria.

Authors:  Abiu Sempere; Belén Viñado; Ibai Los-Arcos; David Campany; Nieves Larrosa; Nuria Fernández-Hidalgo; Dolors Rodríguez-Pardo; Juan José González-López; Xavier Nuvials; Benito Almirante; Laura Escolà-Vergé
Journal:  Antimicrob Agents Chemother       Date:  2022-09-14       Impact factor: 5.938
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.